New Trial for Linagliptin and Patients with Type 2 Diabetes

New Trial for Linagliptin and Patients with Type 2 Diabetes

linagliptinEli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on March 19, 2013 the initiation of a novel clinical trial for linagliptin. Coined MARLINA, this Phase IIIb trial will evaluate the glycemic efficacy and safety of linagliptin in patients with type 2 diabetes who have prevalent albuminuria. This patient population, suffering from albuminuria, will be evaluated while continuing to remain on standard therapy for the treatment of diabetic nephropathy. Researchers have determined that in diabetic patients with a type 2 diagnosis have elevated levels of blood glucose which can damage the filters of their kidneys. This damage often leaves these type 2 patients at a high risk for developing  renal impairment. Albumin leakage is one of the first signs of early –stage renal disease and kidney damage, making this study extremely pertinent for this patient group.  The goal of this study is to document a change from the baseline HbA1c of patients after roughly six months of treatment. This study is slated to be completed in 2014.

Linagliptin has been in the pharmaceutical spotlight within the past year, tagged as being an effectual API to combat type 2 diabetes – previous Linagliptin news.

American Association of Clinical EndocrinologistsA retrospective analysis of linagliptin data was presented on May 6, 2013 at the AACE 22nd Annual Scientific & Clinical Congress. The data analysis and presentation focused on specific subsets of patients, specifically the Hispanic and Latino groups. All of the patients documented in the presentation had type 2 diabetes for ten years or longer. The use of linagliptin showed marked improvement in blood sugar levels for all of the patient subsets across the studies and data compiled. Type 2 diabetes has become a worldwide problem and accounts for 90% – 95% of all diabetes cases, which creates a global need for effective and safe treatment options until a cure is found. The patent for Tradjenta {linagliptin} expires on April 24, 2017.

Linagliptin, CAS# 668270-12-0, is available from LGM Pharma for research and development purposes. Clients can be assured of complete support throughout the entire R&D process, as well as quality API products.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service